Ascentage Pharma to Present 17 Clinical Advances at 2026 European Hematology Association Congress ROCKVILLE, MD and

Ascentage Pharma to Present 17 Clinical Advances

at 2026 European Hematology Association Congress

ROCKVILLE, MD and SUZHOU, China, May 12, 2026

- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX:

6855), a global, integrated biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies

for cancers and other diseases, announced today that 17 clinical advances of its core assets will be featured at the 31st Congress

of the European Hematology Association (EHA2026), including 8 poster presentations. The abstracts feature data from ongoing clinical studies

encompassing Olverembatinib (HQP1351), China's first approved third-generation BCR-ABL inhibitor, and Lisaftoclax (APG-2575), the

first approved China-developed Bcl-2 selective inhibitor. The EHA2026 Congress will convene in Stockholm, Sweden, from June 11 to

As one of the most authoritative and influential

international academic meetings in hematology, the EHA Congress aggregates hematology professionals from around the world to share the

latest research advances and breakthrough clinical data.

Key abstracts of accepted poster presentations

UPDATED EFFICACY AND SAFETY OF OLVEREMBATINIB

(HQP1351) AS SECOND-LINE THERAPY IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML)

EFFICACY OF OLVEREMBATINIB IN PATIENTS WITH

CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) WITH PRIOR RESISTANCE TO PONATINIB OR ASCIMINIB AND ASXL1 MUTATIONS

UPDATED RESULTS OF POLARIS-1 (PART 1), A GLOBAL

REGISTRATIONAL PHASE 3 STUDY: OLVEREMBATINIB COMBINED WITH LOW-INTENSITY CHEMOTHERAPY IN NEWLY DIAGNOSED PH+ ALL

CORRELATION OF BASELINE CHARACTERISTICS WITH

PROGNOSIS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) TREATED WITH LISAFTOCLAX (APG-2575) IN A

PIVOTAL PHASE 2 STUDY

SAFETY AND PRELIMINARY EFFICACY OF OLVEREMBATINIB

(HQP1351) COMBINED WITH LISAFTOCLAX (APG-2575) IN PEDIATRIC PATIENTS WITH RELAPSED/REFRACTORY (R/R PH+ ALL): RESULTS OF A PHASE 1B STUDY

All abstracts (including Posters Presentation

and Publication Only) are available on the EHA website.

About Ascentage Pharma

Ascentage Pharma Group International (NASDAQ:

AAPG; HKEX: 6855) ("Ascentage Pharma" or the "Company") is a global, commercial stage, integrated biopharmaceutical

company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs

in cancer. The Company has built a rich pipeline of innovative drug products and candidates that include inhibitors targeting key proteins

in the apoptotic pathway, such as Bcl-2 and MDM2-p53, next-generation kinase inhibitors, and protein degraders.

The Company's first approved product, Olverembatinib,

is the first novel third-generation BCR-ABL1 inhibitor approved in China for the treatment of patients with CML in chronic phase (CML-CP)

with T315I mutations, CML in accelerated phase (CML-AP) with T315I mutations, and CML-CP that is resistant or intolerant to first and

second-generation TKIs. It is covered by the China National Reimbursement Drug List (NRDL). Ascentage Pharma is currently conducting an

FDA-cleared registrational Phase III trial, called POLARIS-2, of Olverembatinib for CML, as well as registrational Phase III trials for

patients with newly diagnosed Ph+ ALL, called POLARIS-1, and SDH-deficient GIST patients, called POLARIS-3.

The Company's second approved product, Lisaftoclax,

is a novel Bcl-2 inhibitor for the treatment of various hematologic malignancies. Lisaftoclax has been approved by China's National

Medical Products Administration (NMPA) for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma

(CLL/SLL) who have previously received at least one systemic therapy including Bruton's tyrosine kinase (BTK) inhibitors. The Company

is currently conducting four global registrational Phase III trials: the FDA-cleared GLORA study of Lisaftoclax in combination with BTK

inhibitors in patients with CLL/SLL previously treated with BTK inhibitors for more than 12 months with suboptimal response; the GLORA-2

study in patients with newly diagnosed CLL/SLL; the GLORA-3 study in newly diagnosed, elderly and unfit patients with AML; and the FDA-cleared

GLORA-4 study in patients with newly diagnosed higher risk MDS.

Leveraging its robust R&D capabilities, Ascentage

Pharma has built a portfolio of global intellectual property rights and entered into global partnerships and other relationships with

numerous leading biotechnology and pharmaceutical companies, such as Takeda, AstraZeneca, Merck, Pfizer, and Innovent, in addition to

research and development relationships with leading research institutions, such as Dana-Farber Cancer Institute, Mayo Clinic, National

Cancer Institute and the University of Michigan. For more information, visit https://ascentage.com/

Cautionary Note Regarding Forward-Looking Statements

This press release includes forward-looking statements

within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended,

and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, contained

in this press release may be forward-looking statements, including statements that express Ascentage Pharma's opinions, expectations,

beliefs, plans, objectives, assumptions or projections regarding future events or future results of operations or financial condition.

These forward-looking statements are subject to a number of risks and uncertainties as discussed in Ascentage Pharma's filings with

the SEC, including those set forth in the sections titled "Risk factors" and "Cautionary note regarding forward-looking

statements" in its Annual Report on Form 20-F for the year ended December 31, 2024, filed with the SEC on April 16, 2025, the sections

headed "Forward-looking Statements" and "Risks Factors" in the prospectus of the Company for its Hong Kong initial

public offering dated October 16, 2019, and other filings with the SEC and/or The Stock Exchange of Hong Kong Limited where the Company's

ordinary shares are listed it has made or it makes from time to time that may cause actual results, levels of activity, performance or

achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking

statements contained in this presentation do not constitute profit forecast by the Company's management.

As a result of these factors, you should not rely

on these forward-looking statements as predictions of future events. The forward-looking statements contained in this press release are

based on Ascentage Pharma's current expectations and beliefs concerning future developments and their potential effects and speak

only as of the date of such statements. Ascentage Pharma does not undertake any obligation to update or revise any forward-looking statements,

whether as a result of new information, future events or otherwise.

Stephanie Carrington